Wugen is developing off-the-shelf cellular therapies for cancer
Our NK cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer cells. Our NK cell and CAR-T immuno-oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML) and T-cell malignancies.
At Wugen, we are developing off-the-shelf:
NK cell therapies targeting solid tumors and hematologic malignancies
CAR-T cell therapies targeting T-cell malignancies
Our issued and pending patents support and protect a strong pipeline of convenient, off-the-shelf therapies that are developed to treat patients with cancer.